NanoMedSyn, with its work on lysosomal storage disease, was supported by patient organizations such as “Vaincre les Maladies Lysosomales” (VML), VML-Swiss, “Association Française contre les Myopathies” (AFM), Rétinostop, the ARC foundation, and the Ligue contre le cancer. It was also supported by institutional partners (Inserm, CNRS, University of Montpellier) incubators of life science companies like Eclosion, Languedoc Roussillon Initiative (LRI), Transferts-LR and Eurobiomed. Finally, it gets also a European support with the FEDER.
NanoMedSyn collaborates with several CNRS research institutes (Montpellier), INSERM/AP-HP (Paris), CEA (Bagnols-sur-Cèze) and GTP technology (Toulouse) in France. NanoMedSyn’s overseas partners are from University of California, San Diego (USA), the McGill University in Montreal (Canada) and Shire, Boston (USA) for research and development on lysosomal storage disease therapy and research on personalized nanomedicine targeting.